Biotechnology company Anivive Lifesciences revealed on Wednesday the launch of two pre-clinical studies to further evaluate the in vivo efficacy, safety and the therapeutic potential of antiviral GC376 as both a treatment for COVID-19 and other coronavirus related diseases.
Earlier this year, the company has submitted a pre-Investigational New Drug (pIND) request for GC376 with the Food and Drug Administration (FDA) to advance the programme for use in humans. It has licensed the exclusive worldwide rights to GC376 from Kansas State University for use as a treatment in both humans and animals.
The company said GC376 is a novel, first-in-class, small molecule protease inhibitor with a favorable therapeutic index demonstrated in preclinical studies. A common feature of viruses in the picornavirus-like supercluster is a 3C or 3C-like protease responsible for viral replication. GC376 has been shown to be a potent inhibitor of this protease across all coronaviruses with a high therapeutic index.
In addition, the viruses in this family include human coronavirus 229E, transmissible gastroenteritis virus of swine (TGEV), murine hepatitis virus (MHV), bovine coronavirus (BCV), feline infectious peritonitis virus (FIPV), severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East Respiratory Syndrome (MERS) as well as COVID-19 (SARS-CoV-2), concluded the company.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial